BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Go back to BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints| (NASDAQ: DRMA) | Delayed: 1.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.63 | 52 Week High | $ | |||
| Open | $1.63 | 52 Week Low | $ | |||
| Day High | $1.63 | P/E | N/A | |||
| Day Low | $1.63 | EPS | $ | |||
| Volume | 19,561 | |||||
| (NASDAQ: DRMAW) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $ | |||
| Open | $0.00 | 52 Week Low | $ | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $ | |||
| Volume | 12,473 | |||||
